Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Central Pharmaceutical JSC No2's Equity-to-Asset or its related term are showing as below:
HSTC:DP2's Equity-to-Asset is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 0.48 * Ranked among companies with meaningful Equity-to-Asset only.
Central Pharmaceutical JSC No2 (HSTC:DP2) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Central Pharmaceutical JSC No2 Equity-to-Asset Related Terms
Central Pharmaceutical JSC No2 Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Central Pharmaceutical JSC No2 Equity-to-Asset Chart
Central Pharmaceutical JSC No2 Annual Data
Trend
Equity-to-Asset
Central Pharmaceutical JSC No2 Semi-Annual Data
Equity-to-Asset
HSTC:DP2 vs : Equity-to-Asset Comparison
For the Pharmaceutical Retailers subindustry, Central Pharmaceutical JSC No2's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Central Pharmaceutical JSC No2 Equity-to-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Central Pharmaceutical JSC No2's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Central Pharmaceutical JSC No2's Equity-to-Asset falls into.
Central Pharmaceutical JSC No2 Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Central Pharmaceutical JSC No2 (HSTC:DP2) has a Equity-to-Asset of 0.00 as of . 20. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Central Pharmaceutical JSC No2 and its competitors.
Is Central Pharmaceutical JSC No2's Equity-to-Asset too high?
Central Pharmaceutical JSC No2's current Equity-to-Asset is 0.00. Overall, Central Pharmaceutical JSC No2 has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Central Pharmaceutical JSC No2's Equity-to-Asset compare to ?
Central Pharmaceutical JSC No2's Equity-to-Asset of 0.00 can be compared against companies in the Healthcare Providers & Services industry. The industry median Equity-to-Asset is 0.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Healthcare Providers & Services company?
The median Equity-to-Asset among Healthcare Providers & Services companies is 0.48, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Central Pharmaceutical JSC No2 and its competitors. For the Healthcare Providers & Services industry, the median Equity-to-Asset is 0.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Central Pharmaceutical JSC No2's current Equity-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Central Pharmaceutical JSC No2 stock overvalued right now?
Central Pharmaceutical JSC No2 (HSTC:DP2) has a current Equity-to-Asset of 0.00. The current Equity-to-Asset is 0.00. Central Pharmaceutical JSC No2's overall GF Score™ is 23/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Central Pharmaceutical JSC No2 (HSTC:DP2), the current Equity-to-Asset is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Central Pharmaceutical JSC No2 is engaged in the Trading of medicinal materials, pharmaceutical materials, chemicals, essential oils, modern medicines, traditional medicine drugs, cosmetics, and nutritious foods. Some of its products include Gentamycin injection solution 80; Genatreson Skin Cream; Ferimax Hard Capsules and others.
23GF Score
Get the complete analysis for HSTC:DP2
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HSTC:DP2 has been successfully added to your 
